1naresh

Array
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)
1nareshArray
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)

Table 2: 
Results of literature search^a
Study No.^b FU Time (mo) % Inactive Patients (Placebo) Efficacy Measure
Absolute % Increase in Inactive Patients Lesion No. (All Patients) Lesion Volume (All Patients) Lesion Volume (Active Patients)
Oral temsirolimus 120 9 25% +2% −26% −29% −26%
Glatiramer acetate 239 9 5% −2% −33%^c −42% −43%
Natalizumab 
    3 mg 139 6 32% +43% −88% −87% −64%
    6 mg 145 6 32% +33% −82% −76% −54%
Oral fingolimod 
    1.25 mg 164 6 47% +30% −43% −50% +16%
    5 mg 158 6 47% +35% −61% −63% +10%
Overall mean effect 13% 56% 58% 27%

Note:—FU indicates follow-up.


↵a Effects shown are the percentage increase in active patients, the percentage change in mean or median number of lesions, the percentage change in mean lesion volume in the complete cohort, and the percentage change in mean lesion volume in active patients.


↵b Total number of participating patients in trial.


↵c Median lesion number.